ISRCTN60931429已完成未知

Clinical trial of the effect of oral administration of magnesium threoninate (L-TAMS) in morphine analgesia and tolerance

Xinhua Hospital (affiliated with Shanghai Jiaotong University School of Medicine)0 个研究点目标入组 116 人开始时间: 2018年1月24日最近更新: 2024年2月27日

适应症

试验速览

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36703238/ (added 14/02/2024)

•1. Subjects voluntarily signed the informed consent
•2. Patients suffering from cancer pain with treatment of morphine, aged from 18 to 80 regardless of gender
•3. Survival time is expected to exceed 3 months
•4. Moderate to severe pain, VAS >4 points or more, or outbreak of pain >3 times/day
•5. Patients can follow the drug dose and follow-up plan
•6. Patients can describe the symptoms, no serious infection, respiratory insufficiency and has the ability to cooperate
•7. Non-allergic persons
•8. No drug abuse or drug addiction
•9. Non-lactating, pregnant women. Subjects who did not have a pregnancy plan within 1 month after the test
•10. Patients did not participate in a drug test within 3 months before this test (including the test drug)

•1. Researchers think that there is any reason they can't be included
•2. In poor situation, severe systemic infection or respiratory dysfunction and uncooperative
•3. Suffering from severe respiratory system, cardiovascular system diseases, liver and kidney dysfunction, cancer
•4. Patients who are allergic to magnesium threonate (L-TAMS)
•5. Patient who has a history of drug abuse
•6. Breastfeeding, gestational women or subjects who do not have a pregnancy plan within 1 month after the test
•7. Patients who participated in a drug trial within 3 months before this trial
•8. Patients does not meet the inclusion criteria

发起方

Xinhua Hospital (affiliated with Shanghai Jiaotong University School of Medicine)